Author

K. R. Lynch

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Organism:yeast· 1

Frequent Co-Authors

T. Huang· 3 shared Y. Kharel· 2 shared A. Gaultier· 1 shared A. J. Mendelson· 1 shared A. Merchak· 1 shared B. E. Isakson· 1 shared B. N. Desai· 1 shared C. A. Doyle· 1 shared

Activity by Year

2017-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

T. Huang

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Assessing Spns2-dependent S1P Transport as a Prospective Therapeutic Target

K. R. Lynch, Y. Kharel, T. Huang, K. Dunnavant, D. Foster, W. Santos, W. Xu, A. Gaultier, A. Merchak, N. Leitinger, C. Pavelec, S. B. Abbott, G. M. Souza, K. T. Nimchuk, J.-B. Shin, , Z. J. Juskiewicz

This study evaluates a novel S1P transport blocker, SLF80821178, showing efficacy in multiple sclerosis without the cardiac side effects of SRMs, but with less lymphopenia and unchanged lymph S1P levels.

bioRxiv · Mar 26, 2024 · PreprintPharmacology & Toxicology

Novel TRPM7 inhibitors with potent anti-inflammatory effects in vivo

G. W. Busey, M. C. Manjegowda, T. Huang, W. H. Iobst, S. S. Naphade, J. A. Kennedy, C. A. Doyle, P. V. Seegren, K. R. Lynch, B. N. Desai

This study identifies novel TRPM7 inhibitors with potent in vivo anti-inflammatory effects, showing efficacy in a mouse model of endotoxemia.

bioRxiv · May 22, 2023 · PreprintImmunology

Saccharomyces cerevisiae as a platform for assessing sphingolipid kinase inhibitors

Y. Kharel, S. Agah, T. Huang, A. J. Mendelson, P. Barkey-Bircann, O. T. Eletu, J. Gesualdi, J. S. Smith, W. L. Santos, K. R. Lynch

The paper describes a high-throughput assay using Saccharomyces cerevisiae to assess sphingolipid kinase inhibitors and validates it with recombinant enzymes.

bioRxiv · Aug 17, 2017Biochemistry